For the quarter ending 2025-09-30, CAPR had -$3,730,816 decrease in cash & cash equivalents over the period. -$19,744,630 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -24,570,647 | -50,302,385 |
| Loss on disposal of fixed assets | -6,846 | -150,673 |
| Depreciation and amortization | 494,726 | 891,728 |
| Stock-based compensation | 3,997,348 | 9,129,091 |
| Restricted stock awards granted | 0 | 257,461 |
| Changes in lease liabilities | 377,280 | -33,688 |
| Receivables | -342 | -10,308,980 |
| Prepaid expenses and other current assets | 966,329 | -198,243 |
| Accounts payable and accrued expenses | 971,647 | 2,844,166 |
| Net cash used in operating activities | -19,688,787 | -26,555,731 |
| Purchase of marketable securities | 58,214,848 | 78,177,790 |
| Proceeds from sales and maturities of marketable securities | 78,175,291 | 119,207,807 |
| Purchases of property and equipment | 55,843 | 1,183,745 |
| Payments for leasehold improvements | 8,531 | 375,008 |
| Payments for construction in progress | 3,945,048 | 1,031,264 |
| Net cash provided by investing activities | 15,951,021 | 38,440,000 |
| Proceeds from exercise of stock awards and warrants | 6,950 | 69,934 |
| Net cash provided by financing activities | 6,950 | 69,934 |
| Net increase in cash and cash equivalents | -3,730,816 | 11,954,203 |
| Cash and cash equivalents at beginning of period | 11,286,996 | - |
| Cash and cash equivalents at end of period | 19,510,383 | - |
CAPRICOR THERAPEUTICS, INC. (CAPR)
CAPRICOR THERAPEUTICS, INC. (CAPR)